Ensuring a compliant QP release can be overwhelming—especially when every decision impacts your company’s GMP certification status. One overlooked deviation or undocumented activity can delay market access or trigger regulatory consequences. According to EudraLex Volume 4, every step must be traceable and aligned with GMP principles. In this article, we’ll clarify the precise responsibilities of a Qualified Person (QP), helping you ensure every release is legally compliant and fully meets EU GMP expectations.
What is a QP release and why is it critical for maintaining a GMP certificate?
In the EU pharmaceutical industry, no medicinal product batch can reach the market without formal certification by a Qualified Person (QP). This certification—commonly referred to as QP release—confirms that the batch was produced in full compliance with both the marketing authorization and applicable quality and regulatory standards: EU GMP guidelines (Annex 16, EudraLex Vol. 4).
A valid GMP certificate is a prerequisite for this process. Issued by regulatory authorities, it verifies that a manufacturing site follows Good Manufacturing Practice principles. Without it, the QP has no legal basis to certify a batch, regardless of its analytical results or documentation.
The release process involves a careful review of production records, laboratory data, deviations, and quality assurance documentation. The QP ensures that each product has been manufactured and tested under a quality system that meets regulatory expectations. This includes a thorough GMP audit to verify compliance with GMP standards.
Failure to meet any part of this duty can result in serious regulatory outcomes—product recalls, withdrawal from the market, or even the suspension of manufacturing operations. Personally, we’ve seen how even a minor oversight can spiral into a full-blown inspection finding—prevention and diligence are everything.
At Billev Pharma East, we help pharmaceutical organizations navigate the legal and procedural complexities of product certification. Our experts ensure that quality systems are aligned with regulatory requirements, supporting every release with confidence and full compliance.
Ultimately, the QP’s sign-off is not just an internal milestone—it’s a legally binding act that rests on robust documentation, a qualified team, and an active, inspection-ready GMP framework.
How does a Qualified Person ensure full compliance before a QP release?
Before certifying a batch, a Qualified Person must evaluate every aspect of a batch’s production, testing, documentation and also verify compliance with both the terms of the Marketing Authorization and the requirements of EudraLex Volume 4 (particularly Annexes 15 and 16). QP must confirm that the batch has been manufactured in accordance with an active GMP certificate.
To ensure compliance, QPs carry out independent batch record reviews, cross-check deviations, verify the status of raw materials, and ensure the site has passed a recent GMP audit. This structured approach builds trust in the release process and ensures legal accountability.
QPs must remain up to date with current regulatory requirements and company-specific SOPs. Even minor lapses in documentation or deviations can prevent a successful QP release.
From our own experience, maintaining an internal audit-ready mindset is the QP’s best tool—it ensures preparedness for both regulatory inspections and routine certification decisions. At Billev Pharma East, we emphasize the importance of this mindset to help pharmaceutical organizations stay ahead of potential challenges.
What must align between QP release and GMP certificate for a compliant batch release?
For a batch to be released to the market, several elements must align to meet regulatory expectations. Most importantly, the production process and associated quality systems must operate within the scope defined by the company’s GMP certificate.
The Qualified Person must verify that the site is authorized to manufacture the specific product type, that validated processes have been followed, and that all relevant data is complete and compliant. This alignment ensures that the release decision is based on more than just test results—it’s backed by a fully controlled and certified environment.
If a manufacturing step, material, or subcontracted activity falls outside what is covered by the active certification, the QP cannot approve the batch. Oversights like this risk regulatory non-compliance and could lead to formal warnings or suspension of certification.
The entire batch release process depends on the strength of the underlying quality system and its documented compliance with Good Manufacturing Practice. Without this foundation, the QP has no reliable framework for decision-making.
In short, the relationship between product release and the company’s manufacturing certification is not optional—it’s essential. Ensuring this alignment helps protect patient safety, product integrity, and long-term regulatory trust.
What documentation is required to support a compliant QP release?
To perform a legally valid and fully compliant QP release, the Qualified Person must rely on a complete and traceable documentation package that proves the batch was manufactured in accordance with the company’s GMP certificate.
The documentation must clearly demonstrate that all critical steps—from raw material approval to final testing—were performed under controlled conditions. Any gaps or inconsistencies can jeopardize the QP release and raise questions about compliance with GMP standards.
Essential documents typically include:
- batch Manufacturing and Packaging Records.
- Certificates of Analysis for finished product and key raw materials.
- Deviations and investigation reports, with root cause and CAPA.
- Cleaning logs, environmental monitoring results, and equipment calibration records.
- Quality control data and approval signatures.
- Confirmation that all activities fall within the scope of the valid GMP certificate.
Before certifying the batch, the QP must verify that every record is complete, accurate, and consistent with internal procedures and regulatory requirements. The documentation must not only prove product quality—it must also demonstrate that the batch was handled in an environment governed by a current GMP certificate.
If the supporting records are incomplete or indicate non-conformance, the QP release must be delayed until all issues are resolved. Regulatory inspectors pay close attention to documentation during audits, and poor record-keeping is a frequent cause of findings.
Ultimately, well-maintained documentation supports the integrity of both the QP release decision and the site’s overall GMP compliance, reinforcing trust in the product and the manufacturer.
Can a QP release be performed without a valid GMP certificate?
The short and definitive answer is no—a QP release cannot be legally performed if the manufacturing site does not hold a valid GMP certificate. This certificate is the regulatory foundation that confirms a facility’s compliance with Good Manufacturing Practice and is a prerequisite for any batch release by a Qualified Person.
Even if the product has passed all analytical tests and appears to meet specifications, the absence of a valid GMP certificate renders the QP release legally invalid. That’s because regulatory authorities don’t just assess the final product—they evaluate the entire manufacturing system, including equipment, personnel, documentation, facilities, and processes. All these elements must be certified under GMP for a QP release to be considered compliant.
In practice, this means that the QP must always confirm the status of the site’s GMP certificate before releasing a batch. If the certificate has expired, been suspended, or withdrawn, the QP is obligated to withhold batch release—even if commercial pressure exists. Releasing a batch under these circumstances can have severe legal consequences, including product recalls, fines, or suspension of the QP’s authorization.
Additionally, for contract manufacturing organizations (CMOs), the QP must also verify that the GMP certificate of each third-party manufacturing or testing site involved in the batch is valid and within scope. Every participant in the supply chain must meet GMP standards to support a compliant QP release.
Ultimately, the integrity of the QP release process is only as strong as the underlying GMP certificate. Without it, there is no regulatory assurance, and no legal pathway for product distribution.
How do deviations and CAPAs affect the QP release process?
Deviations and CAPAs (Corrective and Preventive Actions) are critical elements that directly impact the success of a QP release. Even if a batch meets all quality specifications, unresolved or improperly documented deviations can prevent the Qualified Person from certifying the product for market.
For a release to be compliant, all deviations must be thoroughly investigated, and CAPAs must demonstrate effective resolution. This is essential not only for product safety, but also for maintaining the integrity of the site’s GMP certificate. Regulatory authorities expect manufacturers to handle deviations systematically and transparently, with full traceability.
Below is a table outlining how different types of deviations can affect the QP release process:
| Deviation Type | Risk Level | Required CAPA? | Impact on QP Release |
|---|---|---|---|
| Minor documentation error | Low | Optional | May proceed with justification and QP approval |
| Out-of-spec result (OOS) | High | Mandatory | Batch may be rejected until full investigation is closed |
| Process deviation | Medium–High | Required | QP must assess impact and effectiveness of CAPA |
| Repeated deviation | High | Strong CAPA needed | Signals systemic issue; QP may block release |
| Uninvestigated deviation | Critical | Not applicable | QP release not allowed; high risk to GMP compliance |
Why CAPA quality is essential for a compliant QP release and GMP certificate maintenance
A weak or insufficient CAPA can jeopardize both the QP release and the validity of the GMP certificate. The strength of a CAPA system directly influences whether a QP release can proceed confidently and compliantly. If a deviation is inadequately addressed or the CAPA is vague, repetitive, or delayed, it signals weaknesses in the quality system. This can lead to regulatory scrutiny and may put the GMP certificate at risk.
To maintain both the release process and certification status, CAPAs must:
- identify and eliminate true root causes.
- Include specific, timely actions to prevent recurrence.
- Be documented clearly and implemented effectively.
- Include follow-up to confirm effectiveness.
EudraLex Part I, Chapter 1 (Pharmaceutical Quality System), emphasizes preventive action as a key element of GMP and a Qualified Person cannot approve a batch unless these elements are in place. Strong CAPA management not only supports the validity of each QP release, but also plays a vital role in demonstrating that the site continues to operate in compliance with its GMP certificate.
What role does batch record review play in securing a QP release under GMP?
Batch record review is one of the most important responsibilities in the QP release process. Batch records must be clear, accurate, and complete. Annex 15 and 16 both require that all manufacturing, packaging, testing, and storage activities are recorded and reviewed before release.
The record must reflect the reality of the batch—not just checkboxes. We’ve often found that a strong batch record is like a story: it should explain the who, what, when, where, and how without raising questions.
A thorough review confirms:
- all manufacturing steps were followed as per approved instructions.
- Critical parameters remained within limits.
- In-process controls and test results are compliant.
- No unexplained anomalies are present.
Failure to conduct an in-depth review can lead to product quality failures or regulatory action. The review must be detailed, traceable, and performed by the QP or a delegated QA team member, who ultimately supports the QP’s decision to release the batch under a valid GMP certificate.
How often must GMP systems be audited to support continuous QP release compliance?
Regular auditing of GMP systems is crucial to sustaining reliable QP release operations. Both internal and external audits serve to confirm ongoing compliance with GMP standards and the conditions of the GMP certificate.
Internal audits are typically performed at least once a year, or more frequently in high-risk areas. These proactive checks allow organizations to identify and correct issues before they affect product quality or delay batch release.
Regulatory agencies also conduct periodic inspections, and a failed audit can lead to suspension of the GMP certificate, halting all QP releases until the issue is resolved. For this reason, maintaining a culture of quality and readiness is essential for uninterrupted product supply.
Additionally:
- Results must feed into the site’s continuous improvement plan.
- QPs must assess the audit status of any third-party facilities.
- Regulatory inspections may occur with little notice.
Read also:
- GMP checklist guide: how to prepare for successful GMP audits step by step
- Why are GMP guidelines and GMP requirements essential for compliance?
- What steps must a QP follow to ensure a proper QP release and uphold the GMP certificate?
Sources: 1 – Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, 2 – Regulation (EU) 2019/6 on veterinary medicinal products – includes QP responsibilities for veterinary batches, 3 – PIC/S – Guide to Good Manufacturing Practice for Medicinal Products.